Interim Report January – September 2022
Copenhagen, Denmark, 24 November 2022 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) hereby publishes the interim report for the period January 1 – September 30, 2022. The interim report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.Curasight’s CEO Ulrich Krasilnikoff comments: “It has been a busy first nine months of the year for Curasight as we progressed our pipeline of products under our theranostic platform, combining uTRACE[®] diagnostics and uTREAT[®] therapy with the aim of providing improved cancer